Citigroup maintains Sana Biotechnology at Buy, lowers price target to $11 from $12
Citigroup kept its Buy rating on Sana Biotechnology but reduced its price target from $12 to $11, an 8.3% cut. The new target suggests a 444.6% upside from the Nov 13 closing price of $2.02, according to the bank.

